µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º CP'-CQ\Q
H:_`]X"
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ @e7+d@O<
21[F%,{.),
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) ?xet:#R'
3:(`#YY
1. ICAM-1 meWAm?8RI
9wC; m :
2. interleukin 12(IL-12) Sf8d|R@O
rBf?kDt6l
3. tumor infiltrating lymphocyte Ml Z`g,{
2YyZiOMSc
4. TCR/CD3 complex NP8TF*5V
GpL#,q Yc
5. hematopoietin receptor family ]YP?bP,:
pA'A<|)K0
6. individual idiotype(IdI) 4lA+V,
#
P `"7m-
7. integrin F0Hbklr
Qx;A; n!lw
8. colony-stimulatory factor (CSF) e`r;`a&
a"}#HvB+
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ]B4mm__
L])w-
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? @3YuV=QfH
Gq/6{eRo\
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ rzDJH:W{2
4- _lf(#i
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠKdu\`c-lB
vLv@ Mo
4. ¼òÊö¿¹ÔÌá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ X vMG09
Hs=N0Sk]j
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) Z4ioXl
#Hi]&)p_
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔÀí¡£ I^(#\vRW
NxO^VUD
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) D|j\ nQ
bs EpET
3. immunoglobulin superfamily (IgSF) Ir"Q%>K0f
p''"E$B/(
4. selectin _G #"B{7
) Zo_6%
5. anti-idiotypic antibody (¦ÁId) -MU.Hu
6\fMzm
6. major histocompatibility complex(MHC) 5}bZs` C
l@rwf$-
7. immunotolerance fTV|?:C{
{lTxB'W@d
8. biological reponse modifier(BRM) }?]yxa ~
H9VXsFTW
9. immune reponse gene (Ir gene) 7k=F6k0)
]]=fA 4(
10. reshaped antibody (or reconstituted antibody)
hMeqs+
n<<=sj$\!
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ? x"HX|n
N^
s!!Sbpq
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ n5+S"
@>fO;*
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? 4[#6<Ixf
kg:
uGP9
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ U M( l%
w^])(
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? %x}&=zx0*1
g+ }s:9
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ |ck
ZyDA
lH)em.#
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? w}j6.r
d]CviQUq
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ h41$|lonU%
m0|Ae@g~3
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ 6Q2orn[
,v*p
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔÀíºÍ½á¹û²â¶¨? ?""\
B;GxfYj
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ mQJ4;BJw
E kBae=
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: #vj#! 1
G@!_ZM8h
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: q%-&[%l
-BA"3 S
̉񧄤 As@ihB+(\
^]$$)(jw
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© G{kj}>kS_
0)d?Y
1. CD8 _0,"vFdj
K2cq97k,d
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) rIeM+h7W n
ybZ}
3. immunoglobulin fold(Ig fold) !2}rtDE
2GSgG.%SSM
4. cadherin (Ca-dependent cell adhesion moleculers) NW{y%Z
f.||P
H
5. idiotype-anti-idiotypic antibody immune network theory 0VzXDb>`
u3 ]Uxy
6. HLA class II antigen 3->,So0Y
LeY+p]n~
7. complementarity-determining region (CDR) ^vpIZjN
5
k69F
8. perforin(or pore-forming protein ,PFP) 16I&7=S,
0$tjNye
9. high affinity IL-2 receptor 6sPk:5
8;TAb.r
10. artificial active immunization #(6) ^ (
&vCeLh:s
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© Pg/T^n&
bFg*l$`5
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ:
(gZgMT
MY!q%
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 6O9iEc,HM
-I ?z-?<D
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ XYe~G@Q Z
SBTPTb
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ Gzw@w{JBL
iU5P$7.p
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔÀí¡£ }X]\VSF{
~wOTjz
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? :\b|dvI<
Lz@$3(2
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ GAw(mH*
/kB|1gFj
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ EyY],W1 Y
XE1$K_m
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ M+poB+K.
%<}<'V0
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ ;~+]! U
/[K_
&